Low serum miR‐223 expression predicts poor outcome in patients with acute myeloid leukemia

BACKGROUND: Identification of biomarkers for acute myeloid leukemia (AML) is important for treating this malignancy. Recent studies have reported that microRNAs (miRNAs) are stably detectable in the blood/plasma and can be used as biomarkers for various types of cancer including AML. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guopan, Yin, Zhao, He, Han, Zheng, Zhongxin, Chai, Yanyan, Xuan, Li, Lin, Ren, Wang, Qiang, Li, Jie, Xu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083432/
https://www.ncbi.nlm.nih.gov/pubmed/31691380
http://dx.doi.org/10.1002/jcla.23096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083432/
https://www.ncbi.nlm.nih.gov/pubmed/31691380
http://dx.doi.org/10.1002/jcla.23096

Ejemplares similares